RedHill Biopharma Advances RHB-102 in GI Indications and GLP-1 Therapy Support

RedHill Biopharma ( (RDHL) ) has issued an update.

On January 5, 2026, RedHill Biopharma announced further development progress for its proprietary once-daily extended-release ondansetron formulation RHB-102 (Bekinda) across multiple gastrointestinal indications, including a planned Phase 2 proof-of-concept study targeting gastrointestinal side effects associated with GLP-1/GIP receptor agonist therapies used for diabetes and weight loss. Supported by positive U.S. Phase 3 data in gastroenteritis/gastritis, Phase 2 data in IBS-D, a favorable pharmacokinetic study in oncology support, and decades of ondansetron use, RedHill is pursuing U.S. FDA approval of RHB-102 under the 505(b)(2) pathway for oncology support (with potential expansion to post-operative nausea and vomiting) and positioning the drug as a once-daily oral option that could reduce GI-driven discontinuation of GLP-1 treatments, potentially enhancing its partnership appeal and strengthening the company’s presence in the fast-growing GI and metabolic therapy support markets.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

Spark’s Take on RDHL Stock

According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.

RedHill Biopharma’s overall stock score is primarily influenced by its challenging financial performance, characterized by significant losses and high leverage. The technical analysis suggests a bearish trend, further impacting the score. The absence of valuation metrics and earnings call data limits a comprehensive assessment, resulting in a low overall score.

To see Spark’s full report on RDHL stock, click here.

More about RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused primarily on the U.S. development and commercialization of drugs for gastrointestinal and infectious diseases and oncology. The company markets Talicia, an FDA-approved therapy for Helicobacter pylori infection in adults, and runs late-stage clinical programs including the oral SPHK2 inhibitor opaganib in collaboration with U.S. government and academic partners for multiple indications.

Average Trading Volume: 964,030

Technical Sentiment Signal: Sell

Current Market Cap: $5.25M

Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.